Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy has previously been contraindicated in solid organ transplant recipients. This was due to lack of data and concern for interactions with immunosuppressive drug regimens. However, in post-lung transplant recipients, CFTR modulators may improve extrapulmonary manifestations of cystic fibrosis without impacting graft function or immunosuppressive drug levels. Herein, we present our single center experience with the use of elexacaftor/tezacaftor/ivacaftor, Trikafta, in adult post-lung transplant recipients.

中文翻译：

---

CFTR 调节剂在肺移植后受者中的应用

囊性纤维化跨膜电导调节剂(CFTR) 调节剂治疗以前在实体器官移植受者中是禁忌的。这是由于缺乏数据和担心与免疫抑制药物方案的相互作用。然而，在肺移植后的受者中，CFTR 调节剂可以改善囊性纤维化的肺外表现，而不影响移植物功能或免疫抑制药物水平。在此，我们介绍了我们在成人肺移植后接受者中使用 elexacaftor/tezacaftor/ivacaftor、Trikafta 的单中心经验。